Invention Grant
- Patent Title: ADAMTS-13 mutant
- Patent Title (中): ADAMTS-13突变体
-
Application No.: US12666051Application Date: 2008-06-19
-
Publication No.: US08685665B2Publication Date: 2014-04-01
- Inventor: Kenji Soejima
- Applicant: Kenji Soejima
- Applicant Address: JP Kumamoto-shi
- Assignee: The Chemo-Sero-Therapeutic Research Institute
- Current Assignee: The Chemo-Sero-Therapeutic Research Institute
- Current Assignee Address: JP Kumamoto-shi
- Agency: Oblon, Spivak, McClelland, Maier & Neustadt, L.L.P.
- Priority: JP2007-164531 20070622; JP2008-020012 20080131; JP2008-020177 20080131
- International Application: PCT/JP2008/061211 WO 20080619
- International Announcement: WO2009/001743 WO 20081231
- Main IPC: C12Q1/37
- IPC: C12Q1/37
Abstract:
A method of enhancing an enzymatic activity of a disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) by substituting on or more positions in the isolated human ADAMTS-13.
Public/Granted literature
- US20120064057A1 NOVEL ADAMTS-13 MUTANT Public/Granted day:2012-03-15
Information query
